Gujarat Themis Biosyn Limited
Gujarat Themis Biosyn announced a postal ballot to seek shareholder approval for two special resolutions. These include increasing the company's borrowing limits and enhancing inter-corporate loan and investment limits.
May 06 2026 12:05:00
Gujarat Themis Biosyn Ltd - 506879 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Gujarat Themis Biosyn Ltd initiated a postal ballot to secure shareholder approval for enhancing its borrowing capabilities under Section 180(1)(c) and increasing investment/loan limits under Section 186. This move provides the company with greater financial flexibility for future growth.
May 06 2026 12:05:00
Gujarat Themis Biosyn Limited
Gujarat Themis Biosyn will conduct a postal ballot to obtain shareholder approval for two special resolutions. These resolutions aim to increase the company's borrowing limits and enhance the limits for providing inter-corporate loans, guarantees, and making investments.
May 05 2026 21:05:00
Gujarat Themis Biosyn Limited
Gujarat Themis Biosyn will conduct a postal ballot to obtain shareholder approval for two special resolutions. These resolutions aim to increase the company's borrowing limits and enhance the limits for providing inter-corporate loans, guarantees, and making investments.
May 05 2026 21:05:00
Gujarat Themis Biosyn Limited
Gujarat Themis Biosyn seeks shareholder approval via postal ballot to increase borrowing limits and authorize loans/investments, each up to Rs. 3,500 crores. These actions are crucial for funding growth, capacity expansion, strategic investments, and a planned acquisition from Sanofi.
May 05 2026 21:05:00
Gujarat Themis Biosyn Ltd - 506879 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Gujarat Themis Biosyn seeks shareholder approval to raise borrowing limits to ₹3,500 crores and inter-corporate loan/investment limits to ₹3,500 crores. These measures are crucial for funding business expansion and the acquisition of Sanofi's anti-tuberculosis and anti-infective brands.
May 05 2026 21:05:00
Gujarat Themis Biosyn Limited
Gujarat Themis Biosyn acquired 13 branded generic products from Sanofi for Euro 158 million (₹1,740 crores). This strategic acquisition aims to strengthen its global pharmaceutical platform and expand its presence in the anti-infective segment across over 55 countries.
Apr 24 2026 00:04:00
Gujarat Themis Biosyn Limited
Gujarat Themis Biosyn acquired 13 branded generic products from Sanofi for Euro 158 million (₹1,740 crores). This strategic acquisition aims to strengthen its global pharmaceutical platform and expand its presence in the anti-infective segment across over 55 countries.
Apr 23 2026 23:04:00
Gujarat Themis Biosyn Limited
Gujarat Themis Biosyn Limited acquired Sanofi's global Anti-TB and Anti-Infective Portfolio for approximately €158 million. The acquired portfolio boasts €62 million in FY25 revenue, 13 established brands, and a presence in 55+ countries, structured as an asset acquisition.
Apr 23 2026 23:04:00
Gujarat Themis Biosyn Limited
Gujarat Themis Biosyn Ltd (GTBL) is acquiring Sanofi's Global Anti-TB and Anti-Infective Portfolio for EUR 158 million, a strategic move to strengthen its global pharmaceuticals platform and expand into regulated markets. This acquisition, expected to close by Q3FY27, is poised to enhance GTBL's international presence.
Apr 23 2026 23:04:00
Read More